Mazdutide (codes IBI362 / LY3305677) is a once-weekly GLP-1/glucagon dual agonist based on oxyntomodulin — a natural gut hormone that already hits both receptors. Originally discovered by Eli Lilly and licensed to Innovent Biologics, it's been developed mainly in China, where its phase 3 obesity data have been among the first for a GLP-1/glucagon agent in that market.
Research Background
Oxyntomodulin is a proglucagon-derived hormone that activates both the GLP-1 and glucagon receptors, but like other natural peptides it's too short-lived to use directly. Mazdutide is a synthetic oxyntomodulin analog with a fatty-acid side chain added for weekly dosing. Its development has run from phase 1b dose-ranging (2022) through phase 2 trials in both obesity and type 2 diabetes (2022–2024) to the pivotal phase 3 GLORY-2 obesity trial, all conducted in Chinese adults.
How It Works
The GLP-1 receptor arm drives glucose-dependent insulin secretion and central appetite suppression. The glucagon receptor arm adds increased energy expenditure and reduced hepatic fat. The historical challenge with GLP-1/glucagon coagonists is balance — glucagon can raise blood sugar and work against GLP-1's glucose-lowering — but mazdutide appears to tune that ratio so glycemic control holds while the metabolic and weight benefits come through.
What the Research Shows
- Obesity, phase 2 (Ji et al., Nature Communications, 2023): over 24 weeks, mean body-weight change was about -6.7%, -10.4%, and -11.3% across the 3, 4.5, and 6 mg doses, versus roughly +1% for placebo.
- Obesity, phase 3 GLORY-2 (JAMA, 2026): at the 9 mg dose over 60 weeks, mean weight change was about -16.7% versus -1.5% for placebo, and roughly 84% of participants lost at least 5% of body weight (versus about 33% on placebo).
- Type 2 diabetes, phase 2 (Diabetes Care, 2024): HbA1c fell by roughly 1.4 to 1.7 percentage points with mazdutide over 20 weeks, versus essentially no change on placebo, alongside meaningful weight loss.
Storage & Handling
Mazdutide is supplied in lyophilized (freeze-dried) form. Store it at -20°C or below, protected from light and moisture. Reconstitute immediately before use with a sterile solvent, and avoid repeated freeze-thaw cycles.
Frequently Asked Questions
What is oxyntomodulin, and why does it matter here?
Oxyntomodulin is a natural gut hormone that activates both the GLP-1 and glucagon receptors. Mazdutide is engineered from it, which is why it's a GLP-1/glucagon dual agonist rather than a GLP-1-only drug.
How is mazdutide different from survodutide?
Both are GLP-1/glucagon dual agonists. Survodutide is a glucagon-based analog developed by Boehringer/Zealand; mazdutide is an oxyntomodulin-based analog developed by Innovent/Lilly and studied primarily in China.
What purity does Dynamite Research Peptides provide?
Our mazdutide is 99%+ purity with a Certificate of Analysis for every batch.
All products are for research use only — not for human or animal consumption.